Avid releases results for PET Alzheimer's agent

Mar 22, 2007

Molecular imaging developer Avid Radiopharmaceuticals of Philadelphia has released results of the company's first clinical study of a new radiopharmaceutical designed to provide PET imaging of Alzheimer's disease.

Avid's AV-1 agent (¹⁸F-AV-1/ZK) is designed to image the beta amyloid plaques that accumulate abnormally in Alzheimer's patients. In the study, researchers were able to determine that AV-1 distinguishes patients with Alzheimer's disease from healthy controls, according to Dr. Christopher Rowe from Austin Hospital of Melbourne. Rowe presented the results at the eighth annual International Conference on AD/PD in Salzburg, Austria.

Rowe said that AV-1 PET scans showed high levels of signal in Alzheimer's patients, particularly in areas of the brain known to contain amyloid plaques. In contrast, there was no retention of AV-1 in the cerebellar cortex, an area where amyloid plaques do not accumulate, according to the company.

By AuntMinnie.com staff writers
March 23, 2007

Avid gets funding for new radiotracer, January 25, 2005

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$